SEC Form 4 · accession 0000886163-16-000130
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Kozarich
Director
Period of report
Jan 20, 2016
Accepted (ET)
Jan 22, 2016 · 7:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 20, 2016 | M | 1,666 | $59.40 | A | 51,377 | D | |
| Common StockF1,F2 | Jan 20, 2016 | S | 300 | $92.71 | D | 51,077 | D | |
| Common StockF1,F3 | Jan 20, 2016 | S | 600 | $93.83 | D | 50,477 | D | |
| Common StockF1,F4 | Jan 20, 2016 | S | 200 | $94.71 | D | 50,277 | D | |
| Common StockF1,F5 | Jan 20, 2016 | S | 200 | $96.28 | D | 50,077 | D | |
| Common StockF1,F6 | Jan 20, 2016 | S | 366 | $97.99 | D | 49,711 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F7 | $59.40 | Jan 20, 2016 | M | 1,666 | D | — | Jan 31, 2016 | Common Stock | 1,666 | 0 | D |
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01,2015, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.24 to $93.24, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.34 to $94.32, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.51 to $94.91, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.23 to $96.33, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.68 to $98.18, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7The option becomes exercisable in twelve successive equal monthly installments upon completion of each calendar month of service beginning 1/31/06.